BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3

NCT01830127 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: Ribavirin
DRUG: BI 207127 high dose
DRUG: Faldaprevir
DRUG: Ribavirin
DRUG: BI 207127 low dose
DRUG: Faldaprevir

Sponsor

Boehringer Ingelheim